Hepatocellular Carcinoma | Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Hepatocellular Carcinoma

published 8 months ago by Dr Neil Love

Featuring a roundtable discussion with Drs Thomas A Abrams, Anthony El-Khoueiry and Robin K Kelley on the following topics: First-Line Systemic Therapy for Patients with Unresectable Hepatocellular Carcinoma (HCC) Recent advances in the management of HCC; the IMbrave150 trial and subsequent approval of atezolizumab with bevacizumab for unresectable HCC (0:00) Rationale for the use of atezolizumab with bevacizumab as first-line therapy; impact of COVID-19 on the management of HCC (1:48) Case: A woman in her mid-50s with advanced HCC receives atezolizumab/bevacizumab as first-line therapy — Thomas A Abrams, MD (7:06) Activity and tolerability of the combination of atezolizumab and bevacizumab (12:04) Ongoing investigation of pembrolizumab/lenvatinib and atezolizumab/cabozantinib for patients with HCC (16:33) Role of combination immunotherapy approaches versus locoregional therapies for the management of HCC (21:57) Case: A man in his mid-70s with moderately differentiated HCC experiences an improvement in pain with first-line atezolizumab/bevacizumab — Anthony El-Khoueiry, MD (28:35) Case: A man in his late 40s with chronic active hepatitis B is diagnosed with advanced HCC and receives first-line lenvatinib — Robin K Kelley, MD (33:46) Activity and tolerability of lenvatinib versus sorafenib as first-line therapy (36:29) Efficacy and side effects of nivolumab or pembrolizumab/lenvatinib as up-front therapy for HCC (39:50) Case: A man in his late 60s with hepatitis C and alcohol-related cirrhosis is diagnosed with HCC — Dr El-Khoueiry (44:17) Importance of Child-Pugh score in therapeutic decision-making (48:09) Selection of first-line therapy based on Child-Pugh score, symptoms and performance status (52:02) Clinical Decision-Making for Patients with Progressive Metastatic HCC  Choice of therapy for a patient with advanced HCC and disease progression after first-line sorafenib (1:00:54) Selection and sequencing of therapy for patients in the second- and later-line settings (1:06:13) Risks and benefits with cabozantinib or regorafenib for patients with progressive metastatic HCC (1:08:16) Case: A man in his early 70s who underwent a liver transplant for HBV-related cirrhosis receives regorafenib after experiencing disease progression on sorafenib — Dr Kelley (1:12:18) Side effects associated with immunotherapy in patients with HCC (1:16:24) Case: A man in his early 80s with recurrent HCC receives ramucirumab — Dr Abrams (1:19:18) Novel agents and strategies under investigation for the treatment of HCC (1:26:30) CME information and select publications

more episodes from Research To Practice | Oncology Videos